Stocks in play: Zenith Epigenetics Ltd.
Has entered into an agreement with Astellas Pharma Inc. to evaluate ZEN-3694, Zenith’s leading BET inhibitor, in combination with Astellas and Pfizer’s androgen receptor inhibitor, XTANDI (enzalutamide), in patients with metastatic castration resistant prostate cancer (mCRPC). Zenith Epigenetics Ltd. shares T.RVX are trading up $0.02 at $0.93.
Read: Sky-High Demand for Drone Technology Driving Massive Growth